EGFR and neoplasm: PIK3CA amplification or mutations promote tumour infiltration and activate the PI3K/AKT/mTOR pathway, which suggests that PI3K/AKT/mTOR pathway activation might be related to resistance to 3rd-generation EGFR-TKIs [32, 33].